<DOC>
	<DOCNO>NCT02051907</DOCNO>
	<brief_summary>The main purpose study demonstrate safety efficacy KAM1403 GEL reduce symptom mild moderate Radiation Dermatitis . Efficacy evaluate compare symptom assessment post radiotherapy : erythema , desquamation , edema , moist desquamation ulceration KAM1403 Gel treat group versus group subject treat Aloe vera Gel ( control group ) . In addition , comparison make subject ' self evaluation treatment group versus control group . Safety determine number severity Adverse Events Device-Related .</brief_summary>
	<brief_title>Clinical Study Evaluate Safety Efficacy KAM1403 Gel Treat Radiation Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Radiodermatitis</mesh_term>
	<criteria>Female 18 year age Diagnosed breast cancer schedule receive postoperative radiotherapy Treatment regional lymph node ( i.e . axillary , supraclavicular , internal mammary ) allow . Schedule breast radiotherapy ( RT ) dose 50 Gy 2 Gy/fx , 5 week boost lumpectomy cavity . Minimum 3 week chemotherapy start radiation therapy . Patient agree use test product study period Tumor involvement skin Patient another dermatological disease/condition could interfere clinical evaluation include infected atopic dermatitis lesion Patient previous history allergy ingredient test formulation Paget 's disease nipple . Pregnant lactating female</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>